Product Program year 2025 Source: CMS Open Payments

Datroway

Biological Oncology

NDC 65597-801-01

Open in the dashboard

General payments

$1,720,113

1,482 payments

Research payments

$207,550,567

2,707 payments

Through program year 2025, $1,720,113 in general payments and $207,550,567 in research payments were reported against Datroway (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $1,720,113 1,482
2025 Research $207,550,567 2,707

Breakdown

Who paid General payments · program year 2025
  1. AstraZeneca Pharmaceuticals LP $1,587,531 1,399 payments
  2. AstraZeneca UK Limited $132,582 83 payments
Top recipients General payments · program year 2025
  1. Maria Theodoulou Medical Oncology · Albany, NY $62,688 4% · 19 payments
  2. Martin Dietrich Hematology & Oncology · Rockledge, FL $51,696 3% · 40 payments
  3. Hatim Husain Internal Medicine · San Diego, CA $49,338 3% · 26 payments
  4. Wassim McHayleh Hematology & Oncology · Altamonte Springs, FL $48,062 3% · 30 payments
  5. Mohammadbagher Ziari Hematology & Oncology · Corona, CA $46,765 3% · 31 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $928,524 55% · 154 practitioners
  2. Medical Oncology Internal Medicine $453,185 27% · 93 practitioners
  3. Internal Medicine $80,737 5% · 20 practitioners
  4. Nurse Practitioner $67,735 4% · 73 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $28,365 2% · 87 practitioners

The top 5 of 42 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $295,921 17% · 103 recipients
  2. Florida $202,637 12% · 86 recipients
  3. New York $173,732 10% · 55 recipients
  4. Indiana $129,018 8% · 18 recipients
  5. Texas $110,694 6% · 52 recipients

The top 5 of 44 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

1,482 general · 2,707 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record